HPV DNA (Primary) testing
• designed to detect various HPV strains, covering up to
28 high-risk strains linked to cervical cancer,
such as strains 16, 18, 26, 31, 32, 33, 34, 35, 39, 45,
51, 52, 53, 54, 55, 56, 57, 58, 59, 62, 66, 68, 69, 73,
82/MM, 82/IS, 84, and 89, along with 12 low-risk
strains: strains 6, 11, 40, 42, 43, 44, 61, 70, 71, 72, 81,
and 83.
• In case high-risk strains other than 16 and 18
be detected, the company provides complimentary
liquid-based cytology testing.
• HPV 16 and 18 are responsible for up to 70% of cervical
cancers, while HPV 6 and 11 are known to cause genital
warts in 90% of cases in the genital area.
• Results are typically available within 1-7 days.
• The testing process is carried out by medical scientists
under the supervision of gynecologists and pathologists.
• Since its inception in the third quarter of 2021, it has
delivered testing services to over 12,000 cases.
Liquid based cytology (LBC)
• Capable of identifying abnormal cells that heighten the
risk of cervical cancer.
• Offers superior accuracy in screening compared to
traditional methods like the Pap smear.
• The sampling kit used is certified by international
standards organizations, including ISO13485 and the
Korea FDA, and it is registered with the Food and Drug
Administration in Thailand.
• This test is interpreted by a specialized pathologist, and
the results are summarized by a gynecologist.
• Results are available within a 3-7 day timeframe.
• Since its inception in the third quarter of 2021, it has
delivered testing services to over 14,000 cases.
